Streetbeat News

Products Services

RSI

Delaware Lottery has launched its first online sportsbooks and relaunched its three online casinos, all powered by Rush Street Interactive (RSI). Delaware residents aged 21 and over can now place bets on various devices including mobile phones, tablets, desktops, and laptops.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:09 pm

MXCT

MaxCyte, Inc. (MXCT) has entered into a partnership with Lion TCR to support the global expansion of Lion TCR's TCR-T cell therapy pipeline. This collaboration aims to enhance the development and commercialization of TCR-T cell therapies for infectious diseases and cancers.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:09 pm

ICCM

A new study has found that IceCure Medical's ProSense system, which is used in cryoablation procedures to destroy tumors, may also enhance the immune response against cancer by boosting CD8+ T cell response. This supports previous studies and suggests that ProSense could offer additional anti-cancer benefits beyond just tumor destruction.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:09 pm

DYN

Dyne Therapeutics Inc (NASDAQ:DYN) reported positive initial clinical data from its ACHIEVE trial for DM1 and DELIVER trial for DMD, showing dose-dependent efficacy and a favorable safety profile. The data suggest that DYNE-101 and DYNE-251 could be more effective than the current standard of care, eteplirsen. The company plans to provide the next update in 2H of 2024. DYN shares surged 41.50% in premarket trading.

Portfolio Pulse from Vandana Singh

January 03, 2024 | 1:07 pm

KROS

Keros Therapeutics has announced its intention to develop KER-065 for the treatment of obesity, signaling a potential expansion of its product pipeline into metabolic disorders.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:05 pm

WKSP

Worksport has announced a strategic partnership with NeuronicWorks for the manufacturing and assembly of the COR Battery System, which is gearing up for its Alpha release. NeuronicWorks will supply circuit boards and perfect the construction of the full unit.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:04 pm

INO

Inovio Pharmaceuticals plans to submit a marketing application to the FDA for INO-3107, aimed at treating Recurrent Respiratory Papillomatosis, in the second half of 2024. The company anticipates being prepared to launch the treatment in 2025.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 1:03 pm

AGIO

Agios Pharmaceuticals' stock is up following the announcement that its Phase 3 ENERGIZE study of Mitapivat achieved its primary and key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:56 pm

JNJ

Elektrofi has entered into an exclusive agreement with Janssen Biotech, a subsidiary of Johnson & Johnson, to develop up to five programs using Elektrofi's formulation technology. Elektrofi will receive an upfront payment of $18M and could earn over $155M in future milestones for each target. This partnership could lead to the development of up to 12 unique products with Elektrofi's partners.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:55 pm

BYDDF

BYDDY

TSLA

BYD Co. Ltd. (OTC:BYDDY) (OTC:BYDDF) surpassed Tesla, Inc. (NASDAQ:TSLA) in Q4 sales volume, sparking debates among social media users and Tesla enthusiasts. Elon Musk emphasized that Tesla is an AI/robotics company, not just a car manufacturer. Tesla fans argue that BYD's success is limited to China and lacks Tesla's technological edge, such as full-self-driving (FSD) software. Despite Tesla's Cybertruck not generating expected excitement, analysts are hopeful about Tesla's future, especially with the anticipated $25K model. Ark Invest maintains a $2,000 price target for Tesla by 2027, with robotaxi operations being a significant value driver.

Portfolio Pulse from Shanthi Rexaline

January 03, 2024 | 12:44 pm